Dexametasona transtimpánica para el tratamiento de la enfermedad de Ménière de difícil manejo

Abstract

Abstract Introduction: Ménière’s disease is characterized by recurrent episodes of vertigo, sensorineural hearing loss and aural fullness, which can be incapacitating and cause stress and anxiety. Aim: To assess the effect of transtympanic steroid injections on hearing and vertigo for patients suffering from intractable Ménière’s disease. Material and Method: Patients with intractable Ménière’s disease were recruited and treated with three transtympanic steroid injections (dexamethasone 4 mg/ml). Audiometric and vestibular assessment, and two dizziness questionnaires (DHI, UCLA-DQ) were performed upon recruitment, three weeks, and ten weeks following the transtympanic treatment. A brief auto-perception survey was applied at 6 months follow-up. Results: Twelve patients completed the study. An increase in the mean auditory threshold was observed up to 11.25 dB, mainly between 125 and 3000 Hz at three weeks, and a reduction of these up to 7.5 dB at ten weeks with respect to the initial ones, mainly between 125 and 2000 Hz (not statistically significant). All patients presented vestibular dysfunction on caloric testing. A significant impro-vement in the UCLA-DQ survey score was observed, remaining throughout the follow-up. No statistically significant differences were found in the overall score or subcomponents of the DHI. Seven out of eight patients reported that they would undergo the injections again. Conclusion: Transtympanic corticosteroids can help to reduce disability and impact on the quality of life of patients with Ménière’s disease that is difficult to manage in the medium and long term.